Clinical and Bioanalytical Insights in the Research and Development of Respiratory drugs

Substantial success has been realized in the treatment of common respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory allergies. By acquiring a deeper understanding of inflammatory mechanisms, new targets for treating these diseases are becoming available. Consequently, researchers are poised to unlock potential advances in research for unmet medical needs for often life-threatening respiratory disorders such as cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), and an infectious diseases such as Respiratory Syncytial Virus (RSV).



The use of biomarkers such as inflammatory cytokines and more specific biomarkers in blood and sputum provide for studying intermediate endpoints. For large-scale respiratory trials, alternative emerging pharmacodynamic evaluations will be presented that can fill the gap in sensitive outcome measurements.



Learning

This webinar will provide an R&D update in the respiratory area and cover the need to increase the performance of clinical trials by using new biomarkers and efficient study designs, based on modeling and simulation exercises and new site management models.